plant-made H1 VLP influenza vaccine

The plant-made H1 VLP influenza vaccine (also known as H1-VLP) is an investigational monovalent virus-like particle (VLP) vaccine developed by Medicago for the prevention of H1N1 influenza. Produced via transient expression of the influenza hemagglutinin (HA) surface glycoprotein in the plant *Nicotiana benthamiana*, the vaccine consists of self-assembled VLPs that mimic the native structure of the influenza virus but lack any viral genetic material. In a Phase 1 clinical trial (NCT01302990), the safety, tolerability, and immunogenicity of varying non-adjuvanted doses of the H1 VLP vaccine were evaluated in healthy adults, demonstrating that the vaccine was safe, well-tolerated, and capable of inducing robust humoral and cell-mediated immune responses. Although development of this specific monovalent candidate did not proceed to approval, the technology served as the foundation for Medicago's subsequent quadrivalent influenza VLP vaccine program.

Other names

Dose given at Day 0H1 VLPH-1 VLPH 1 VLPH1 VLP influenza vaccineH-1 VLP influenza vaccineH 1 VLP influenza vaccineH1-VLPH-1-VLPH 1-VLPH1-VLP vaccineH-1-VLP vaccineH 1-VLP vaccineH1N1 VLP influenza vaccineH-1N1 VLP influenza vaccineH 1N1 VLP influenza vaccineH1N1 VLP vaccineH-1N1 VLP vaccineH 1N1 VLP vaccineplant-derived H1 VLP influenza vaccine